Open Clinical Trials at The University of Chicago (353 trials):

Leukemia Cancer Studies Currently Recruiting Participants at the University of Chicago Cancer Research Center

Study Number Title
4186 Etiology Of Alkylator-Induced Myeloid Leukemia
6492
8299 CALGB 9665: The CALGB Leukemia Tissue Bank
9902 CALGB 9862: Molecular Genetic Features of Acute Lymphoblastic Leukemia (Optional Companion to CALGB 19802)
16654A S0535: A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia
09-130-B A University of Chicago Leukemia Registry Protocol.
10-583-A AML08: A Phase III Randomized Trial of Clofarabine, Plus Cytarabine Versus Conventional Induction Therapy and a Phase III Study of Natural Killer Cell Transplantation in Patients With Newly Diangosed Acute Myeloid Leukemia
10-064-B Molecular characterization of hematopoietic malignancies
10-371-B A Phase I Dose-Escalation Study of LY2090314 in Patients with Acute Leukemia.
10-571-A S0805: Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) with or without Allogeneic Stem Cell Transplant in Patients with Philadelphia (Ph) Chromosome Positive and/or Bcr-Abl Positive Acute Lymphoblastic Leukemia (ALL) (a BMT Study)
10-616-A A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
10-622-A E1908: A Phase II Randomized Trial Comparing Standard and Low Dose Rituximab: Initial Treatment of Progressive Chronic Lymphocytic Leukemia in Elderly Patients using Alemtuzumab, and Rituximab
10-617-A COG AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
11-0002 CALGB 10701:A Phase II Study of Dasatinib (Sprycel®) (IND #73969, NSC #732517) as Primary Therapy followed by Transplantation for Adults >/= 50 Years with Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG, SWOG and NCIC CTG
11-0014 Evaluation of patients with hematopoietic malignancies and their family members for mutations in RUNX1, CEBPA, and p53.
11-0027 A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients with Solid Tumor or Hematologic Malignancy (V212-011)
11-0050 A Phase III, Multicenter, Randomized, Controlled Study to Assess the Efficacy and Safety of ON 01910.Na Administered as a 72-Hour Continuous Intravenous Infusion Every Other Week in Myelodysplastic Syndrome Patients with Excess Blasts Relapsing After, or Refractory to, or Intolerant to Azacitidine or Decitabine (Protocol 04-21).
11-0545 Randomized phase I study combining suppression of T regulatory cells with WT1 vaccine therapy for AML patients in complete remission
11-0197 An Open-Label, Phase 1 Study of Inotuzumab Ozogamicin in Subjects with Relapsed or Refractory CD22-Positive Acute Lymphocytic Leukemia.
11-0175 A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (VALOR)
11-0207 CALGB 11001: A Phase II Study Incorporating Sorafenib Into The Therapy of Patients ≥ 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia
11-0300 A Phase 1, Dose Escalation, Multicenter Study of Two Subcutaneous Regimens of SGI-110, a DNA Hypomethylating Agent, in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)
11-0376 A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Relapsed or Refractory Acute Lymphoblastic Leukemia.
11-0619 An open label assessment of safety and efficacy of Ruxolitinib (INCB018424) in subjects with primary myelofibrosis, post essential thrombocythemia-myelofibrosis and post polycythemia vera-myelofibrosis who have platelet counts of 50 x109/L to 100 x109/L.
11-0270 Pharmacokinetics, Safety and Tolerability of Intravenous Posaconazole Solution followed by Oral Posaconazole Suspension (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1B) (P05520)
11-0650 An open label, multicenter, phase II study to evaluate efficacy and safety of the BiTE antibody blinatumomab in adult patients with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL)
11-0647 A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects >/= 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
11-0667 CALGB 11002: A Randomized Phase II Trial of Decitabine-Based Induction Strategies for Patients >/= 60 Years Old With Acute Myeloid Leukemia (AML)
12-0111 Phase I investigation of the feasibility of combining 5-azacytidine with highdose cytarabine (HiDAC) and mitoxantrone chemotherapy in a sequential manner for remission induction in high-risk acute myelogenous leukemia (AML)
11-0743 A Phase I, Open- Label, Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of V212/Inactivated Varicella- Zoster Virus (VZV) Vaccine in Adults with Hematologic Malignancies Receiving Treatment with Anti- CD20 Monoclonal Antibodies (V212- 013)
12-0153 A phase 1b study to evaluate the safety and preliminary efficacy of PF-04449913, an oral hedgehog inhibitor, in combination with intensive chemotherapy, low dose ara-C or decitabine in patients with acute myeloid leukemia or high risk myelodysplastic syndrome.
12-1038 A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
12-1136 S1117, A Randomized Phase II Study of Azacitidine in Combination withLenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
12-1267 A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.